Regeneron Pharmaceuticals

A large retrospective multicenter study of 2,405 eyes found no increased risk of glaucoma or ocular hypertension with high-volume intravitreal agents avacincaptad pegol, pegcetacoplan, and aflibercept 8mg compared to standard 50 µL injections.

Strand Therapeutics closed a $153 million Series B funding round led by Kinnevik, with participation from major pharmaceutical companies including Eli Lilly, Amgen, and Regeneron Ventures.

Sensei Biotherapeutics reported Q2 2025 financial results with $28.6 million in cash to fund operations into Q2 2026, while advancing its lead cancer immunotherapy solnerstotug.

The FDA declined to approve Regeneron's lymphoma therapy odronextamab for the second time, citing manufacturing issues at a third-party Catalent facility rather than safety or efficacy concerns.

Sensei Biotherapeutics will present clinical data from the Phase 1 dose expansion cohort of solnerstotug, a pH-selective anti-VISTA antibody, at ESMO Congress 2025 in Berlin.

Ryan Richardson will step down as Chief Strategy Officer from BioNTech's Management Board on September 30, 2025, after serving since January 2020.

Regeneron Pharmaceuticals and Intellia Therapeutics are conducting a two-part clinical study evaluating REGV131-LNP1265, a CRISPR/Cas9-based gene insertion therapy for hemophilia B patients.

Hengrui Pharma and Kailera Therapeutics' dual-acting obesity drug HRS9531 demonstrated 18% weight loss in a Phase 3 trial in China, significantly outperforming placebo by 16%.

Health Canada has extended approval of Evkeeza (evinacumab) to treat children as young as 6 months old with homozygous familial hypercholesterolemia (HoFH), a devastating inherited cholesterol disorder.

Regeneron Pharmaceuticals and BioNTech SE are conducting a Phase 2 clinical trial evaluating the combination of investigational cancer vaccine BNT116 with cemiplimab versus cemiplimab monotherapy in advanced non-small cell lung cancer patients with PD-L1 expression ≥50%.